Cardiovascular Complications In Cancer Therapy

This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.

Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: • Cardiac complications in patients receiving cancer therapy • The treatment of cancer in patients with cardiovascular disease • The treatment of cardiovascular disease in patients with cancer When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.

Written by experts in cardiovascular disease, hematology, and oncology, The Washington Manual® of Cardio-Oncology: A Practical Guide for Improved Cancer Survivorship is a clinically relevant, easy-to-use primer on the detection, management, and improved cardiovascular-based patient outcomes in adults undergoing treatment for cancer or who have previously survived cancer therapy. Edited by Drs. Daniel J. Lenihan, Joshua D. Mitchell, and Kathleen W. Zhang, this concise yet comprehensive manual provides high-yield information that reflects today’s advances in risk stratification, early diagnosis, and treatment of cardiovascular disease—all in an easy-access, concisely bulleted format for on-the-go reference.

Cardio-oncology is a medical subspecialty concerned with the diagnosis and treatment of cardiovascular disease (CVD) and organ failure mediated by micro- to macro-circulation defects in cancer patients and survivors. The risk of CVD in cancer survivors is eight times higher than the general population, and the relative risk of coronary artery disease and heart failure (HF) is 10 times and 15 times higher, respectively, compared to their siblings without cancer. It is important to note that cancer treatments including chemotherapy and radiation can lead to both short- (< 1 year) and long-term (> 5 years) cardiovascular complications. Previously, Dr. Edward T.H. Yeh initiated the MD Anderson Practice (MAP) project, and published 16 MAPs to provide the current best practice we considered at UT MD Anderson. As shown in these MAPs, one of the key issues of cardio-oncology practice and science is how we can allow cancer patients to receive maximum and uninterrupted treatments for cancer while protecting them from cancer therapy-mediated cardiovascular complications. Therefore, it is crucial to understand not only pathophysiology of CVD, but also mechanistic insights of how each cancer treatment can control cancer growth and metastasis. Without having the profound knowledge in the pathophysiological, clinical and epidemiologic aspects of cardiovascular complications of existing cancer therapy, it is impossible to establish the strong evidence-based strategies and approaches for both short- and long-term cardiovascular complications after cancer treatment. In addition, we believe that cardio-oncology science should not be restricted to deal with the side effects of each specific cancer drug, because many common cardiovascular phenotypes among the different cancer treatments are also observed. This Research Topic provides a comprehensive overview from both of the current research and practice, and a platform for obtaining the logical and up-to-date treatment and prevention of CVD in cancer patients and survivors.

Cardiac complications of cancer treatment present a complex challenge in the care of patients with cancer. Chemotherapy, targeted therapies, radiation, and transplantation can cause life-threatening cardiac effects, sometimes years after completion of therapy, and patients may have preexisting cardiac disease or risk factors that further affect heart function.

A foundational investigation of disorders of the heart resulting from cancer treatment, with conclusions about common mechanisms. Seventeen contributed chapters are arranged in five parts: cytotoxic myocardial disease--preclinical study, cytotoxic myocardial disease--clinical study, myocardial disease--radiation and biologics, pericardial disease, and other cardiovascular disease. Annotation copyright by Book News, Inc., Portland, OR

This concise and handy manual provides straightforward, up-to-date guidance for cardiologists and other practitioners on the management of cancer patients with cardiac problems, whether they be due to the cancer itself or to antineoplastic treatment. Detailed attention is devoted to the various forms of cardiotoxicity associated with chemotherapy and radiotherapy. The drugs commonly responsible for each toxicity are identified and clear advice is offered on monitoring techniques and treatment approaches. In addition, the issue of cardiotoxicity due to cancer treatment in particular patient groups – children, the elderly, and those with pre-existing cardiac disease – is addressed separately, with guidance on when and how antineoplastic (and/or cardiological) treatments should be modified. Further sections describe the correct responses to cardiac problems secondary to the cancer itself, including thromboembolic disorders and electrolyte imbalances, and the diagnosis, treatment, and follow-up of cardiac tumors. A closing section considers how to improve cooperation between oncologists, cardiologists, and general practitioners to ensure that cancer patients’ cardiovascular needs are met in a multidisciplinary approach.

Clinical Cardio-oncology is a comprehensive, clinically focused title for cardiologists, oncologists, and specialists in cardio-oncology programs who need up-to-date knowledge about the cardiovascular effects of cancer treatment, especially on long-term cancer survivors. This brand-new resource covers the implementation of cardio-oncology into your practice, while a strong focus on patient management offers helpful information on coordinating care before, during, and after therapy. Its highly organized four-section format allows readers to quickly and easily locate relevant information. Comprised of four sections for quick and easy reference: Oncology and Hematology Principles; Cardiac Complications from Cancer Therapy; Coordination of Care; and Cardio-oncology in Practice. Provides expert wisdom from cardio-oncology authorities around the world, as well as consultation and perspectives from pioneers in the field of oncology. Highlights the principles of cancer therapies, including radiation and tumor therapy, as well as pre-, intra-, and post-therapy cardiology evaluation. Boasts chapters on implementing cardio-oncology into practice: primary cancer centers, comprehensive referral centers, group practices, and educational needs and goals for fellowship programs. Advises on how to coordinate care for the patient at every stage of treatment (pre-therapy, during therapy, after therapy, and end-of-life). Presents detailed information on various cardiac complications from cancer therapy, such as cardiomyopathy, vascular disease, arrhythmias, and hypertension. Teaches the principles of oncology and hematology with coverage of different therapy types and cardiac tumors. Includes a comprehensive drug guide.